Immunochemotherapy with low-dose subcutaneous alemtuzumab (A) plus oral fludarabine and cyclophosphamide (FC) is safe and induces more and deeper complete remissions in untreated patients with high-risk chronic lymphocytic leukemia (CLL) than chemotherapy with FC alone. An early analysis of the randomized phase-III HOVON68 CLL Trial - Geisler, C H; van't Veer, M MB (Blood (ASH Annual Meeting Abstracts), 2011)
et al.